ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give ADMA Biologics a “Moderate Buy” consensus, with three buy ratings and three hold ratings. The average 12-month price target is $18.67, nearly double the stock’s reported $9.72 price.
• Recent analyst actions were mixed: Raymond James initiated coverage with an “outperform” rating and a $21 target, while Mizuho lowered its target from $20 to $17 but maintained an “outperform” rating.
• ADMA’s latest quarter met earnings expectations at $0.16 per share, while revenue reached $124.39 million, up 2% year over year but slightly below estimates. Institutional investors own 75.68% of the company’s stock.

Shares of ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $18.67.

Several research analysts have recently weighed in on ADMA shares. Raymond James Financial began coverage on ADMA Biologics in a research note on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price target for the company. Mizuho reduced their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Finally, Zacks Research upgraded shares of ADMA Biologics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 2nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Western Wealth Management LLC bought a new position in ADMA Biologics during the 1st quarter valued at about $31,000. Rockefeller Capital Management L.P. boosted its stake in shares of ADMA Biologics by 60.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company's stock worth $82,000 after acquiring an additional 1,694 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in shares of ADMA Biologics during the second quarter worth $42,000. Quantbot Technologies LP purchased a new stake in shares of ADMA Biologics during the second quarter worth approximately $51,000. Finally, Nykredit A S purchased a new position in shares of ADMA Biologics during the second quarter worth about $59,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $9.72 on Monday. ADMA Biologics has a 1 year low of $7.21 and a 1 year high of $20.46. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The company has a 50-day moving average price of $9.43 and a 200-day moving average price of $9.37. The stock has a market capitalization of $2.18 billion, a P/E ratio of 13.89 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business had revenue of $124.39 million for the quarter, compared to analysts' expectations of $125.34 million. During the same period last year, the business earned $0.14 EPS. The business's revenue was up 2.0% on a year-over-year basis. On average, equities research analysts forecast that ADMA Biologics will post 0.78 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company's operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products.

ADMA's commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.